Therapeutic strategies for hepatocellular carcinoma: new advances and challenges (Q41191439)

28 September 2017

title

Therapeutic strategies for hepatocellular carcinoma: new advances and challenges (English)

1 reference

28 September 2017

main subject

hepatocellular carcinoma

1 reference

Sílvia Vilarinho

1

1 reference

28 September 2017

Tamar Taddei

series ordinal

2

1 reference

28 September 2017

publication date

1 June 2015

1 reference

Current treatment options in gastroenterology

28 September 2017

published in

1 reference

28 September 2017

volume

13

1 reference

28 September 2017

issue

2

1 reference

28 September 2017

page(s)

219-234

1 reference

28 September 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Needle tract implantation after sonographically guided percutaneous biopsy of hepatocellular carcinoma: evaluation of doubling time, frequency, and features on CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Lack of tumor seeding of hepatocellular carcinoma after percutaneous needle biopsy using coaxial cutting needle technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Systemic Therapy in Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Systematic review: The model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

The targeted oncolytic poxvirus JX-863 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-863 in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

New frontier in liver cancer treatment: oncolytic viral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Targeted therapies for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Identification of driver genes in hepatocellular carcinoma by exome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

High-resolution characterization of a hepatocellular carcinoma genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Chemopreventive strategies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: A meta‐analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Detection of circulating tumor DNA in early- and late-stage human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Cancer. Circulating tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11938-015-0049-8

Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.

21 January 2018

1 reference

12 December 2020

Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers

1 reference

12 December 2020

Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy

1 reference

12 December 2020

Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson

1 reference

12 December 2020

Systemic therapy for advanced hepatocellular carcinoma: past, present, and future

1 reference

12 December 2020

Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study

1 reference

12 December 2020

Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma

1 reference

12 December 2020

Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis

1 reference

12 December 2020

Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial

1 reference

12 December 2020

Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma

1 reference

12 December 2020

Genomic landscape of liver cancer

1 reference

12 December 2020

A multidisciplinary approach: group dynamics

1 reference

12 December 2020

NCCN clinical practice guidelines in oncology: hepatobiliary cancers

1 reference

12 December 2020

Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma

1 reference

12 December 2020

10.1007/S11938-015-0049-8

Identifiers

DOI

1 reference

Dimensions Publication ID

28 September 2017

1039092022

0 references

1 reference